RU2670488C2 - Новые проникающие в клетку пептиды - Google Patents

Новые проникающие в клетку пептиды Download PDF

Info

Publication number
RU2670488C2
RU2670488C2 RU2015113378A RU2015113378A RU2670488C2 RU 2670488 C2 RU2670488 C2 RU 2670488C2 RU 2015113378 A RU2015113378 A RU 2015113378A RU 2015113378 A RU2015113378 A RU 2015113378A RU 2670488 C2 RU2670488 C2 RU 2670488C2
Authority
RU
Russia
Prior art keywords
cell
peptide
complex
penetrating
amino acid
Prior art date
Application number
RU2015113378A
Other languages
English (en)
Russian (ru)
Other versions
RU2015113378A (ru
Inventor
Мадиа ДЕРУАЗИ
Пол УОЛКЕР
Пьер-Ив ДИТРИХ
Original Assignee
Юниверсите Де Женев
Лез Опито Юниверситер Де Женев
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Юниверсите Де Женев, Лез Опито Юниверситер Де Женев filed Critical Юниверсите Де Женев
Publication of RU2015113378A publication Critical patent/RU2015113378A/ru
Application granted granted Critical
Publication of RU2670488C2 publication Critical patent/RU2670488C2/ru

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/01—DNA viruses
    • C07K14/03—Herpetoviridae, e.g. pseudorabies virus
    • C07K14/05—Epstein-Barr virus
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/76—Albumins
    • C07K14/77—Ovalbumin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/162—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from virus
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/10—Fusion polypeptide containing a localisation/targetting motif containing a tag for extracellular membrane crossing, e.g. TAT or VP22
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16211—Lymphocryptovirus, e.g. human herpesvirus 4, Epstein-Barr Virus
    • C12N2710/16222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
    • C12N2760/18522—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Transplantation (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Biomedical Technology (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
RU2015113378A 2012-09-13 2013-09-12 Новые проникающие в клетку пептиды RU2670488C2 (ru)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201261700432P 2012-09-13 2012-09-13
EP12184311.4 2012-09-13
EP12184311 2012-09-13
US61/700,432 2012-09-13
PCT/IB2013/058497 WO2014041505A1 (en) 2012-09-13 2013-09-12 Cell penetrating peptides

Publications (2)

Publication Number Publication Date
RU2015113378A RU2015113378A (ru) 2016-11-10
RU2670488C2 true RU2670488C2 (ru) 2018-10-23

Family

ID=46826380

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2015113378A RU2670488C2 (ru) 2012-09-13 2013-09-12 Новые проникающие в клетку пептиды

Country Status (9)

Country Link
US (1) US9657064B2 (enExample)
EP (1) EP2895499B1 (enExample)
JP (1) JP6306593B2 (enExample)
KR (1) KR101861416B1 (enExample)
CN (1) CN104736553B (enExample)
AU (1) AU2013316679B2 (enExample)
CA (1) CA2884677C (enExample)
RU (1) RU2670488C2 (enExample)
WO (1) WO2014041505A1 (enExample)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2842811C1 (ru) * 2019-12-20 2025-07-02 ПиУайСи ТЕРАПЬЮТИКС ЛИМИТЕД Новые способы доставки в клетку
US12698307B2 (en) 2019-12-20 2026-08-04 PYC Therapeutics Limited Cellular delivery methods

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9187534B2 (en) * 2011-03-11 2015-11-17 Universite De Geneve Multi-epitopic vaccine
RU2693487C2 (ru) * 2013-08-07 2019-07-03 Йеда Ресеарч Энд Девелопмент Ко. Лтд. Пептиды, способные реактивировать мутанты р53
US10131690B2 (en) 2014-04-25 2018-11-20 Phi Pharma Sa C6S specific transporter molecules
KR101835554B1 (ko) 2014-06-24 2018-04-19 서울대학교 산학협력단 C/ebp를 포함하는 유도성 t 조절세포 분화촉진 또는 안정화 조성물 및 방법
US10316061B2 (en) 2014-10-02 2019-06-11 Temple University Of The Commonwealth System Of Higher Education Synthesis of cell penetrating peptides for drug delivery and stem cell applications
CN107106668A (zh) * 2014-12-10 2017-08-29 华西亚生医有限公司 用于免疫中的有效抗体生产的新颖蛋白质结构
WO2016146143A1 (en) * 2015-03-16 2016-09-22 Amal Therapeutics Sa Cell penetrating peptides and complexes comprising the same
EP3429618B1 (en) 2016-03-16 2024-02-21 Amal Therapeutics SA Combination of an immune checkpoint modulator and a complex comprising a cell penetrating peptide, a cargo and a tlr peptide agonist for use in medicine
WO2017176081A1 (ko) * 2016-04-07 2017-10-12 (주)네오리젠바이오텍 세포 투과 펩티드
KR101799805B1 (ko) 2016-04-07 2017-11-21 (주)네오리젠바이오텍 세포 투과 펩티드
KR20190057345A (ko) 2016-09-21 2019-05-28 아말 테라퓨틱스 에스에이 암 치료를 위한, 세포 투과 펩타이드, 멀티 에피토프 및 tlr 펩타이드 작용제를 포함하는 융합체
CN106544351B (zh) * 2016-12-08 2019-09-10 江苏省农业科学院 CRISPR-Cas9体外敲除耐药基因mcr-1的方法及其专用细胞穿透肽
EP3360891B1 (en) 2017-02-14 2022-03-30 Karlsruher Institut für Technologie Cell penetrating peptides of human origin
WO2018150196A1 (en) 2017-02-17 2018-08-23 Oxford University Innovation Limited Cell penetrating peptides modified by glycosylation
US11117930B2 (en) 2017-02-23 2021-09-14 Adrx, Inc. Peptide inhibitors of transcription factor aggregation
WO2018226992A1 (en) 2017-06-07 2018-12-13 Adrx, Inc. Tau aggregation inhibitors
CA3073062A1 (en) 2017-08-18 2019-02-21 Adrx, Inc. Tau aggregation peptide inhibitors
CN108070025B (zh) * 2017-10-24 2019-11-19 中山大学附属口腔医院 一种细胞穿透肽和细胞穿透肽复合物及二者的应用
GB201812980D0 (en) 2018-08-09 2018-09-26 Univ Oxford Innovation Ltd Cell-penetrating peptides
GB201812972D0 (en) 2018-08-09 2018-09-26 Univ Oxford Innovation Ltd Cell-penetrating peptides
AU2019394177A1 (en) 2018-12-07 2021-06-10 Oxford University Innovation Limited Linkers
AU2020207087A1 (en) * 2019-01-12 2021-08-12 The Methodist Hospital Self-assembled peptide nanoparticle and use thereof
WO2021135647A1 (zh) * 2019-12-31 2021-07-08 厦门大学 用于胞内递送分子的多聚化递送系统
EP4185603A4 (en) * 2020-07-13 2025-04-09 National University of Singapore PEPTIDE ADDUCANT FOR ITS THERAPEUTIC APPLICATIONS IN THE DEVELOPMENT OF VIRAL AND TUMOR VACCINES AND CANCER IMMUNOTHERAPY AS WELL AS AUTOIMMUNE DISEASE DIAGNOSIS AND TREATMENTS
WO2022079175A1 (en) 2020-10-14 2022-04-21 Boehringer Ingelheim International Gmbh Combination of a sting agonist and a complex comprising a cell penetrating peptide, a cargo and a tlr peptide agonist
CA3211038A1 (en) 2021-02-12 2022-08-18 Oxford University Innovation Limited Cell-penetrating peptide conjugates and methods of their use
FR3143031B1 (fr) * 2022-12-08 2026-06-05 Univ Grenoble Alpes Nouveaux peptides et leur utilisation en tant que transporteurs pour l’internalisation de molécules d’intérêt dans des cellules cibles
FR3154729B1 (fr) * 2023-10-25 2025-10-24 Univ Rouen Normandie Construction comprenant ou constituée d’une séquence peptidique apte à inhiber l’interaction de la filamine A avec le récepteur UT - composition pharmaceutique et produis associés

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999059615A1 (en) * 1998-05-20 1999-11-25 Trimeris, Inc. Hybrid polypeptides with enhanced pharmacokinetic properties
US6337180B1 (en) * 1995-01-04 2002-01-08 L'universite Joseph Fourier Peptide reagent enabling a primary Epstein-Barr virus infection to be detected by testing for the corresponding antibodies, and method for using this reagent
WO2005087797A1 (en) * 2004-03-09 2005-09-22 Microbia, Inc. Methods and compositions for the treatment of gastrointestinal disorders
EA006850B1 (ru) * 2001-07-26 2006-04-28 Иституто Супериоре Ди Санита' Применение биологически активного тат вич-1, его фрагментов или производных для нацеливания на антигенпредставляющие клетки, и/или их активации, и/ или для доставки карго-молекул для профилактической или терапевтической вакцинации, и/или для лечения других заболеваний
WO2011036211A1 (en) * 2009-09-23 2011-03-31 Institut National De La Sante Et De La Recherche Medicale (Inserm) Polypeptides and nucleic acids for treating erbb2-dependent cancers
WO2011135222A2 (fr) * 2010-04-26 2011-11-03 Universite Joseph Fourier Utilisation de peptides comme transporteurs destines a l'internalisation de molecules d'interet dans des cellules cibles

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6479055B1 (en) * 1993-06-07 2002-11-12 Trimeris, Inc. Methods for inhibition of membrane fusion-associated events, including respiratory syncytial virus transmission
US6750008B1 (en) 1999-07-09 2004-06-15 Trimeris, Inc. Methods and compositions for inhibition of membrane fusion-associated events, including HIV transmission
US20060222656A1 (en) 2005-04-01 2006-10-05 University Of Maryland, Baltimore MAGE-A3/HPV 16 peptide vaccines for head and neck cancer
GB0519303D0 (en) * 2005-09-21 2005-11-02 Oxford Biomedica Ltd Chemo-immunotherapy method
WO2011101332A1 (en) 2010-02-16 2011-08-25 Proyecto De Biomedicina Cima, S.L. Compositions based on the fibronectin extracellular domain a for the treatment of melanoma
WO2012027379A2 (en) 2010-08-24 2012-03-01 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Interleukin-13 receptor alpha 2 peptide-based brain cancer vaccines
US9187534B2 (en) 2011-03-11 2015-11-17 Universite De Geneve Multi-epitopic vaccine

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6337180B1 (en) * 1995-01-04 2002-01-08 L'universite Joseph Fourier Peptide reagent enabling a primary Epstein-Barr virus infection to be detected by testing for the corresponding antibodies, and method for using this reagent
WO1999059615A1 (en) * 1998-05-20 1999-11-25 Trimeris, Inc. Hybrid polypeptides with enhanced pharmacokinetic properties
EA006850B1 (ru) * 2001-07-26 2006-04-28 Иституто Супериоре Ди Санита' Применение биологически активного тат вич-1, его фрагментов или производных для нацеливания на антигенпредставляющие клетки, и/или их активации, и/ или для доставки карго-молекул для профилактической или терапевтической вакцинации, и/или для лечения других заболеваний
WO2005087797A1 (en) * 2004-03-09 2005-09-22 Microbia, Inc. Methods and compositions for the treatment of gastrointestinal disorders
WO2011036211A1 (en) * 2009-09-23 2011-03-31 Institut National De La Sante Et De La Recherche Medicale (Inserm) Polypeptides and nucleic acids for treating erbb2-dependent cancers
WO2011135222A2 (fr) * 2010-04-26 2011-11-03 Universite Joseph Fourier Utilisation de peptides comme transporteurs destines a l'internalisation de molecules d'interet dans des cellules cibles

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2842811C1 (ru) * 2019-12-20 2025-07-02 ПиУайСи ТЕРАПЬЮТИКС ЛИМИТЕД Новые способы доставки в клетку
US12698307B2 (en) 2019-12-20 2026-08-04 PYC Therapeutics Limited Cellular delivery methods
RU2855169C1 (ru) * 2020-03-26 2026-01-30 Ларимар Терапьютикс, Инк. Молекулы для органел-специфичной доставки белков

Also Published As

Publication number Publication date
JP2016501829A (ja) 2016-01-21
JP6306593B2 (ja) 2018-04-04
EP2895499A1 (en) 2015-07-22
AU2013316679A1 (en) 2015-03-12
CN104736553B (zh) 2018-10-19
CN104736553A (zh) 2015-06-24
KR20150107708A (ko) 2015-09-23
EP2895499B1 (en) 2019-04-10
RU2015113378A (ru) 2016-11-10
KR101861416B1 (ko) 2018-05-25
US20150239938A1 (en) 2015-08-27
CA2884677C (en) 2020-06-23
AU2013316679B2 (en) 2017-12-14
US9657064B2 (en) 2017-05-23
CA2884677A1 (en) 2014-03-20
WO2014041505A1 (en) 2014-03-20

Similar Documents

Publication Publication Date Title
AU2013316679B2 (en) Cell penetrating peptides
JP7190528B2 (ja) 神経膠芽腫を治療するための細胞透過性ペプチド、カーゴ、及びｔｌｒペプチドアゴニストを含む新規複合体
US12220387B2 (en) Fusion comprising a cell penetrating peptide, a multi epitope and a TLR peptide agonist for treatment of cancer
JP2022017499A (ja) 治療用抗癌ネオエピトープワクチン
US20120231030A1 (en) Multi-epitopic vaccine
CA2702154C (en) A method of transfection and compositions therefor
Barati et al. Immunogenicity and antitumor activity of the superlytic λF7 phage nanoparticles displaying a HER2/neu-derived peptide AE37 in a tumor model of BALB/c mice
JP7628220B2 (ja) 腫瘍関連抗原に由来するペプチド及びリポペプチド及び免疫活性物質からなるアジュバントを含む抗がんワクチン組成物、並びにその使用
EP3773689A2 (en) Antigenic peptides for prevention and treatment of cancer
WO2013006050A1 (en) Peptides inducing or enhancing an immune response against prostate-specific membrane protein (PSMA)
ES2734561T3 (es) Péptidos de penetración celular

Legal Events

Date Code Title Description
HE9A Changing address for correspondence with an applicant